Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hepatic hydrothorax].

S Bozkurt1, J Stein, G Teuber

  • 1Medizinische Klinik I-ZAFES, J.-W.-Goethe-Universität Frankfurt.

Zeitschrift Fur Gastroenterologie
|November 30, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.

Journal of viral hepatitis·2017
Same author

Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection.

Journal of viral hepatitis·2013
Same author

Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial.

Journal of viral hepatitis·2013
Same author

Estimating the likelihood of sustained virological response in chronic hepatitis C therapy.

Journal of viral hepatitis·2010
Same author

Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study.

Journal of viral hepatitis·2010
Same author

Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer?

Gut·2007
Same journal

[Version 7.0 of the S3 Guideline on Ulcerative Colitis sets out clearly defined treatment goals, an open treatment sequence, and a call for improved cross-sectoral care].

Zeitschrift fur Gastroenterologie·2026
Same journal

Zeitschrift fur Gastroenterologie·2026
Same journal

Zeitschrift fur Gastroenterologie·2026
Same journal

[Updated S3 guideline on ulcerative colitis].

Zeitschrift fur Gastroenterologie·2026
Same journal

Zeitschrift fur Gastroenterologie·2026
Same journal

Zeitschrift fur Gastroenterologie·2026
See all related articles

Hepatic hydrothorax, a rare liver cirrhosis complication, involves fluid in the chest. Transjugular intrahepatic portal systemic shunt (TIPS) offers effective treatment for refractory cases.

Area of Science:

  • Hepatology
  • Pulmonology
  • Gastroenterology

Context:

  • Hepatic hydrothorax is a rare complication of liver cirrhosis and portal hypertension.
  • It affects 5-10% of cirrhotic patients with ascites, involving fluid in the chest cavity.
  • The condition arises from fluid migration through diaphragmatic defects.

Purpose:

  • To outline the pathophysiology, clinical management, and treatment options for hepatic hydrothorax.
  • To differentiate hepatic hydrothorax from spontaneous bacterial empyema (SBEM).
  • To highlight the role of transjugular intrahepatic portal systemic shunt (TIPS) and liver transplantation.

Summary:

  • Hepatic hydrothorax involves transudative pleural effusion, distinct from exudative SBEM.
  • Management parallels ascites treatment; refractory cases require advanced interventions.

Related Experiment Videos

  • Spontaneous bacterial empyema (SBEM) affects up to 13% of patients and needs antibiotics.

    • Impact:

    • Transjugular intrahepatic portal systemic shunt (TIPS) placement is highly effective for refractory hepatic hydrothorax, with up to 80% response rates.
    • Liver transplantation is a definitive option for suitable patients.
    • TIPS can serve as a bridge therapy to liver transplantation.